DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) is committed to advancing surgical innovation and today announced the completion of CE marking in the European Union for the expanded indication of the ready-to-use surgical patch HEMOPATCH. HEMOPATCH is now approved in the European Union for use in closing dural defects including excision, retraction or shrinkage of the dura mater following traumatic injury. It is also approved as a hemostatic device and surgical sealant f
![]()
↧